🇺🇸 Sulfadoxine pyrimethamine in United States
25 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 25
Most-reported reactions
- Post Transplant Lymphoproliferative Disorder — 4 reports (16%)
- Anaemia — 3 reports (12%)
- Neutropenia — 3 reports (12%)
- Squamous Cell Carcinoma — 3 reports (12%)
- Arthralgia — 2 reports (8%)
- Aspergillus Infection — 2 reports (8%)
- Cerebral Aspergillosis — 2 reports (8%)
- Colitis — 2 reports (8%)
- Depressed Level Of Consciousness — 2 reports (8%)
- Disseminated Intravascular Coagulation — 2 reports (8%)
Other Infectious Disease approved in United States
Frequently asked questions
Is Sulfadoxine pyrimethamine approved in United States?
Sulfadoxine pyrimethamine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Sulfadoxine pyrimethamine in United States?
Radboud University Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.